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Purpose: In pediatric Hodgkin lymphoma (HL), radiotherapy (RT)-related late toxicities 
are a prime concern during treatment planning. This is the first study to examine whether 
arm positioning (raised versus akimbo) result in differential cardiopulmonary and breast 
doses in patients undergoing mediastinal RT.
Methods: Two treatment plans were made for each patient (akimbo/arms raised); treat-
ment was per Children’s Oncology Group AHOD0031 protocol, including AP/PA fields. 
The anterior midline T6–T7 disk space was used as an anatomic reference of “midline.” 
Heart/lungs were contoured for each setup. For females, breasts were also contoured 
and nipple positions identified. Volumetric centers of contoured organs were defined 
and three-dimensional distances from “midline” were computed. Analyzed dosimetric 
parameters included V5 (volume receiving ≥5  Gy), V10, V15, V20, and mean dose. 
Statistics were performed using the Mann–Whitney test.
results: Fifteen (6 females, 9 males) pediatric HL patients treated with mediastinal RT 
were analyzed. The median lateral distance from the breast center/nipple to “midline” 
with arms akimbo was larger than that with arms raised (8.6 vs. 7.7  cm left breast, 
p = 0.04; 10.7 vs. 9.2 cm left nipple, p = 0.04; 8.7 vs. 7.0 cm right breast, p = 0.004; 9.9 
vs. 7.9 cm right nipple, p = 0.007). Raised arm position was associated with a median 
2.8/3.0 cm decrease in breast/nipple separation, respectively. There were no significant 
differences in craniocaudal breast/nipple position based on arm positioning (p > 0.05). 
Increasing breast volume was correlated with larger arm position-related changes in 
breast/nipple separation (r = 0.74, p = 0.06/r = 0.85, p = 0.02). Akimbo positioning 
lowered median breast V5, V10, V15, and mean dose (p < 0.05), with no differences 
observed in patients with both mediastinal and axillary disease for any parameters 
(p > 0.05). Arm position had no significant effect on cardiopulmonary doses.
conclusion: Akimbo arm positioning may be advantageous to decrease breast doses 
in female pediatric HL patients undergoing mediastinal RT, especially in the absence of 
axillary disease.
Keywords: hodgkin lymphoma, pediatric cancer, secondary malignancy, dosimetry, radiotherapy
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inTrODUcTiOn
Multimodality therapy, namely chemotherapy and radio-
therapy (RT), remains the primary treatment of choice for most 
children and adolescents with Hodgkin lymphoma (HL). With 
this approach, over 95% of favorable subgroup patients can 
be long-term survivors (1). Consequently, this high cure rate 
warrants efforts to reduce treatment-related late morbidities. 
With regard to RT, late effects are related to exposure of nor-
mal tissues [organs at risk (OARs)]. For instance, mediastinal 
irradiation has been associated with late cardiovascular (2) and 
pulmonary toxicity (3), along with increased risks of secondary 
malignancies, including neoplasms of the thyroid, breast, and 
lung (4–6).
Despite major RT paradigm shifts to smaller treatment 
volumes and lower doses, long-term sequelae remain a primary 
concern when treating children and adolescents with RT, and any 
possible therapeutic adaptation to decrease the risk of such seri-
ous complications becomes paramount in such a curable disease. 
One such approach that has been relatively understudied involves 
patient positioning. Specifically, arm positioning for mediastinal 
RT typically follows one of two patterns: with the patient’s arms 
raised above the head, or at the patient’s sides, termed the akimbo 
position. Using these approaches, doses to cardiopulmonary 
OARs as well as breast tissue have, heretofore, not been character-
ized; furthermore, in some academic and community practices, 
arm positioning technique in these patients is simply based on 
physician preference. This study is the first to date to quantify the 
impact of arm position on spatial and dosimetric parameters for 
the heart, lungs, and breast tissue in pediatric HL patients.
MaTerials anD MeThODs
Treatment Planning and Dosimetry
After Institutional Review Board and Ethics Committee 
approval at the University of Nebraska Medical Center, we 
retrospectively identified and reviewed the treatment plans of 
pediatric HL patients treated with mediastinal RT at our insti-
tution from 2008 to 2013. All patients received treatment plan-
ning (including technique, field design/borders, and blocking) 
and delivery per the contemporary children’s oncology group 
(COG) protocol AHOD0031, delivering involved field RT to a 
total dose of 21 Gy in 14 fractions of 1.5 Gy each (7). Prior to 
computed tomography (CT) simulation, all patients underwent 
staging diagnostic CT and/or positron emission tomography 
(PET)-CT (in the arms raised position). Simulation, performed 
supine and with intravenous contrast, included deep inspira-
tion breath hold (DIBH) technique in six patients. In total, 
each patient had two complete treatment plans made, differing 
only in arm position. OARs were manually segmented on a 
slice-by-slice basis (per AHOD0031 and RTOG guidelines, 
when applicable) and organ volumes were recorded, including 
lungs, heart, and bilateral breasts (in female patients). After 
fusion of pre- and post-chemotherapy PET-CT, target volumes 
were contoured and fields designed per the protocol in each 
simulation CT scan. After two treatment plans per patient 
were made (without heterogeneity corrections per protocol), 
multiple dosimetric quantities were then recorded for both 
plans, including V5 [volume (cubic centimeters) receiving 
≥5 Gy], V10, V15, V20, and mean dose for the lungs, breasts, 
and heart.
spatial Position evaluation
In addition to dosimetric calculations, we sought to quantify the 
spatial position of each OAR. Organ position was quantified by 
calculating the three-dimensional distance [superior–inferior 
(z-axis), lateral (x-axis), and anterior–posterior (y-axis)] from 
the anatomic central point (centroid) of each OAR volume to a 
fixed reference point, which was placed at the anterior midline 
T6–7 disk space. This point was chosen because it could be 
reliably demonstrated and reproduced on available axial image 
sequences for all patients, and because it served as a rigid marker 
of the anatomic “midline” of the mediastinum (and thus the 
treatment field given the AP/PA RT technique). Consequently, 
for female patients, the distance (in three dimensions) between 
the centroids of the right and left breasts was calculated relative 
to the midline reference point (the lateral/x-axis measurements 
of this parameter was termed the separation distance). This was 
also performed for three-dimensional distance from each nipple 
to the reference point.
statistical analysis
Statistics, performed using SAS software version 9.4 (Cary, NC, 
USA). Both spatial and dosimetric parameters were performed 
using the Mann–Whitney test. The Pearson product–moment 
correlation coefficient was calculated to evaluate the relationship 
of breast size and arm position-related changes in breast separa-
tion. Paired Student’s t-tests were utilized to compare differences 
in breast volume based on positioning.
resUlTs
Patient Population
During the study period, 27 consecutively treated pediatric HL 
patients were evaluated. Of these, 21 received mediastinal RT. 
Six patients were unable to be analyzed owing to inaccessible or 
corrupted/distorted data. The study group therefore consisted of 
15 patients (6 females, 9 males). Selected clinical characteristics 
of the patient population are shown in Table 1.
Breast spatial analysis
The median breast volume for female patients on the akimbo 
simulation CT was 454.0 (range, 123.8–1063.1) cm3 on the left 
and 443.1 (range, 116.8–982.4) cm3 on the right. Corresponding 
numbers were similar on the raised arm CT, 469.1 (range, 
107.4–1017.1) cm3 and 425.2 (range, 104.8–930.6) cm3, respec-
tively. Neither of these were statistically different between 
positioning groups (p = 0.681 and p = 0.346, respectively).
Spatial measurements are denoted in Table 2. Arm position-
ing most prominently impacted the lateral measurements; the 
median craniocaudal distance from the breast centroid/nipple 
TaBle 2 | arm position-related changes in breast position and separation.
Distance (cm) arm position p-Value change in separation  
distance (cm)
raised akimbo
Nipple to midline Left 9.2 (6.1–10.3) 10.7 (9.8–16.3) 0.04 2.8 (2.3–12.5)
Right 7.9 (7.0–9.3) 9.9 (8.4–14.4) 0.007
Breast centroid to midline Left 7.7 (7.2–8.9) 8.6 (8.1–10.2) 0.04 3.0 (1.5–3.4)
Right 7.0 (6.2–7.7) 8.7 (7.3–9.4) 0.004
Values are expressed as median (range).
TaBle 1 | clinical characteristics of the study population.
Patient gender age BMi (kg/m2) histology Bulky diseasea involved supradiaphragmatic nodal sites (in addition to mediastinum)
1 Male 12 27.3 NS No Bilateral cervical, bilateral axillary
2 Female 13 22.7 NS Yes Left cervical, left axillary
3 Male 13 21.4 NS No Bilateral cervical, bilateral infraclavicular, bilateral axillary
4 Female 13 23.7 NS No Bilateral cervical, left axillary
5 Male 15 36.3 NS Yes Left cervical
6 Female 15 29.3 NS No Bilateral cervical
7 Male 15 21.9 NS No Right cervical
8 Male 15 – NS Yes Bilateral cervical
9 Female 16 30.5 NS No Bilateral cervical
10 Male 16 20.4 NS Yes Bilateral cervical
11 Male 18 25.7 NS No Bilateral cervical
12 Female 17 22.4 NS No Right cervical
13 Female 12 22.9 NS Yes Bilateral cervical, bilateral axillary
14 Male 13 23.1 NS Yes Bilateral cervical
15 Male 15 25.3 NS No Bilateral cervical, right axillary
BMI, body mass index; NS, nodular sclerosis.
aDefinition per AHOD0031.
TaBle 3 | Breast dosimetry in relation to arm positioning.
Breast laterality Technique Mean dose (cgy) V5 (%) V10 (%) V15 (%) V20 (%)
Left Raised 503.2 (223.1–1343.0) 27.2 (10.2–68.3) 21.1 (8.2–61.4) 16.8 (6.5–56.0) 7.5 (2.3–43.5)
Akimbo 194.7 (143.2–1147.2) 9.8 (5.7–66.5) 6.9 (4.2–54.6) 5.5 (3.3–42.9) 3.1 (1.7–26.7)
Right Raised 658.7 (492.3–751.2) 39.8 (28.7–42.3) 28.9 (18.2–32.6) 24.6 (14.0–29.0) 15.9 (2.5–20.8)
Akimbo 422.3 (190.3–565.1) 21.4 (9.0–32.9) 15.8 (5.4–22.0) 13.3 (3.8–18.2) 7.6 (2.4–12.0)
p-Value Raised vs. Akimbo 0.02 0.04 0.02 0.04 0.20
Values are expressed as median (range). cGy, centiGray; Vn, volume of organ (cm3) receiving at least n Gy.
3
Denniston et al. Arm Positioning in Pediatric Hodgkin’s
Frontiers in Oncology | www.frontiersin.org July 2016 | Volume 6 | Article 176
to the T6–7 reference point was not significantly affected by arm 
position for either breast (p > 0.05 for all). The median lateral 
distance from the left breast centroid to midline was 8.6 and 
7.7 cm with arms akimbo and raised, respectively (p = 0.04). 
Corresponding figures from the left nipple to midline were 
10.7 and 9.2  cm with arms akimbo and raised, respectively 
(p = 0.04). Similar results were seen for the right breast cen-
troid to midline (9.9 cm akimbo vs. 7.9 cm raised, p = 0.004) 
and right nipple to midline (8.7 cm akimbo vs. 7.0 cm raised, 
p = 0.007).
In total, the akimbo position was associated with an increase 
in median separation distance of 2.8 and 3.0  cm for the nipple 
and breast centroid, respectively. Moreover, larger breast volumes 
were correlated with larger arm position-related changes in breast 
(Pearson’s r =  0.74, p =  0.06) and nipple (r =  0.85, p =  0.02) 
separation.
Breast Dosimetric analysis
Table 3 illustrates that the akimbo arm positioning significantly 
decreased the breast mean dose (p = 0.02), V5 (p = 0.04), V10 
(p = 0.02), and V15 (p = 0.04), but not V20 (p = 0.20), roughly 
demonstrating at least a twofold numeric improvement in each 
parameter. Of note, three out of the six female patients had medi-
astinal/axillary disease, and the effect of arm positioning in those 
patients was less pronounced. In this subset, the mean breast 
dose (median value) in akimbo versus arms raised conditions 
was 466 cGy and 619 cGy (p = 0.38). Similarly, there were no dif-
ferences in breast V5 (p = 0.30), V10 (p = 0.30), V15 (p = 0.30), 
and V20 (p = 0.81).
cardiopulmonary Oar analysis
Table 4 depicts dosimetric parameters for the heart and lungs, 
for which there were no statistical differences between groups. 
TaBle 4 | cardiopulmonary dosimetry in relation to arm positioning.
Technique Mean heart dose (cgy) Mean lung dose (cgy) lung V10 (%) lung V20 (%)
Raised 866.2 (363.6–1750.3) 755.3 (475.4–1341.4) 32.0 (19.4–63.9) 18.3 (7.9–34.3)
Akimbo 1237.8 (400.6–2136.4) 913.2 (470.9–1345.1) 41.5 (17.6–76.3) 21.2 (9.3–35.1)
p-Value, raised vs. akimbo 0.11 0.56 0.65 0.56
Values are expressed as median (range). cGy, centiGray; Vn, volume of organ (cm3) receiving at least n Gy.
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Additionally, there were no arm position-related changes in 
relative heart or lung position with respect to the reference point 
(p > 0.05 for all directions). The median total lung volume for the 
raised arm CT was 2819 (range, 1539–3308) cm3 vs. 3070 (range, 
1314–5792) cm3 for the akimbo scan (p = 0.15). The median heart 
volume was 618 (range, 439–744) cm3 vs. 569 (range, 396–815) 
cm3 on the arm-raised and akimbo scans, respectively (p = 0.984).
DiscUssiOn
There have been multiple high-quality reports published regard-
ing the development of breast cancer after mediastinal RT for HL; 
a primary theme therein emphasizes the utmost importance of 
measures to decrease breast doses as low as reasonably achievable 
(8–12). This is the first known study that quantitates breast doses 
and spatial parameters based on arm positioning, noting that 
akimbo positioning decreases breast doses and increases breast 
spatial separation, particularly in cases without axillary disease. 
This may be of importance to academic and community practices 
that may position patients at the discretion of the individual 
physician, largely owing to a dearth of data such as that reported 
herein.
It is noteworthy that there were no significant differences in 
craniocaudal breast position between techniques; rather, by far, 
the dominant mechanism of movement is in the medial–lateral 
directions. Hence, though arms raised positioning could be 
theoretically appealing for patients with appropriately located 
mediastinal tumors that could pull breast tissue upwards, this 
is, in fact, not the case. It is possible that the use of a wing-
board versus alpha cradle (which may necessitate differential 
amounts of arm abduction) could change this notion, but there 
is no evidence for this presently. That cardiopulmonary doses 
were different (albeit statistically insignificant) between groups 
warrants further study. Though differences could result from 
positioning, breathing technique, and anatomical causes, larger 
sample sizes are required to confirm whether these differences 
persist.
A notable strength of this work is the relatively homogene-
ous patient treatment per the contemporary COG AHOD0031 
protocol; all patients in this study were treated in the akimbo 
position. It should be mentioned, however, that the protocol 
does not allow multiangle three-dimensional conformal radia-
tion therapy, intensity-modulated RT, or proton beam therapy 
(PBT), contemporary modalities that could theoretically further 
reduce breast doses compared to the AP/PA technique specified 
by the COG protocol. Moreover, it is also important to note 
that these patients were all treated in the era of involved field 
RT, prior to the widespread institution and acceptance of more 
limited RT treatment volumes in HL, such as the currently rec-
ommended involved site radiation (ISRT) (13). Hence, though 
our dosimetric results may not be applicable to these modali-
ties/techniques, our spatial analysis of breast/nipple separation 
distance as a function of arm positioning still applies. Similarly, 
though no statistical differences in breast dosimetric param-
eters were observed in patients with mediastinal and axillary 
diseases, akimbo positioning still offers spatial advantages that 
could translate into dosimetric numerical differences possibly 
deducible with larger sample sizes. Similar work in patients 
treated with other modalities and other subgroups is hence 
needed as an extension of this study. For instance, larger breast 
volumes may stand to benefit to a greater degree from akimbo 
positioning.
The recent rise in PBT to treat not only pediatric cancers but 
also many other neoplasms (14–18) has necessitated greater data 
to support its use. Pediatric malignancies are one of the most 
agreed-upon indications of PBT, and the lower integral dose 
provided may limit occurrence of secondary, radiation-induced 
neoplasms. Application to pediatric HL cases is certainly note-
worthy, as decreased cardiopulmonary and breast doses with 
AP PBT beams may aid in achieving lower incidences of late 
effects to these areas, albeit with virtually no long-term data 
to date.
The major limitation to our study is the use of involved field 
planning; recently, involved site RT has become the standard of 
care in this patient population. However, the AHOD0031 pro-
tocol is a contemporary protocol that was published recently 
in 2014. Many community practices and other countries still 
use involved field RT, and the results of this study are thus 
most applicable to these scenarios. The lack of heterogeneity 
corrections in this protocol is also noteworthy and results 
in higher estimated lung doses. Next, the finding of non-
statistical differences between left and right nipples/centroids 
to midline may be related to individual positioning within 
immobilization frames, excursion of the arm during either 
positioning technique, and/or unforeseen patient rotation. 
Other limitations include not only the retrospective nature but 
also the relatively small sample size. Further research is hence 
needed to corroborate these conclusions, but our statistically 
significant breast dosimetry findings in patients with mediasti-
nal (±cervical) disease cannot be discounted. Though cervical 
disease could impact breast doses, the magnitude is likely low, 
compared with the presence of axillary lymphadenopathy. Our 
non-uniform use of DIBH is another limitation, but studies 
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have demonstrated that its use results in negligible changes to 
breast dose (19, 20).
cOnclUsiOn
Taken together, this is the first report to quantitatively conclude 
that arm positioning in pediatric patients with HL undergoing 
mediastinal irradiation is substantially important to decrease 
breast doses. Further research using larger sample sizes and 
modern, conformal treatment modalities would also be of great 
interest in order to further expand this realm.
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